Primary Hyperoxaluria Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – Alnylam (Oxlumo/lumasiran), Oxthera, Dicerna, Allena Pharmaceuticals, Biocodex
DelveInsight’s “Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Hyperoxaluria Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Primary Hyperoxaluria market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Primary Hyperoxaluria: An Overview
Hyperoxaluria is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes. Additionally, there are dietary factors that can impact urinary oxalate excretion. Primary and secondary hyperoxaluria are two distinct clinical expressions of hyperoxaluria.
Primary Hyperoxaluria (PH) is a rare genetic disease caused by deficiencies in glyoxylate metabolism. Broadly, the PH is inherited in an autosomal recessive fashion and divided into three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). The kidney is the prime target for oxalate deposition, leading to end-stage renal disease in many cases.
Primary Hyperoxaluria Market Key Facts
-
The total prevalent population of PH in 7MM was 11,918 in 2020, which is expected to increase by 2032. However, the majority of the cases remain undiagnosed.
-
The estimates suggest a higher diagnosed prevalence of PH in the United States, with 2,327 diagnosed cases.
-
The estimates suggest a higher diagnosed prevalence of PH Type 1 throughout the 7MM. In the US, out of the total diagnosed prevalent cases of PH, 1,629 were occupied by PH Type 1 alone in the year 2020.
-
Among the European countries, the UK had the highest diagnosed prevalent population of PH with 198 cases, followed by Germany which had diagnosed prevalent population of 171 in 2020. On the other hand, Spain had the lowest diagnosed prevalent population.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Hyperoxaluria market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Primary Hyperoxaluria market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Primary Hyperoxaluria Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Primary Hyperoxaluria Epidemiology Segmentation
-
Total Prevalent Cases of Primary Hyperoxaluria
-
Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
-
Prevalent Cases of Primary Hyperoxaluria
-
Diagnosed Prevalent Cases of Primary Hyperoxaluria
-
Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
-
Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
Primary Hyperoxaluria Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Hyperoxaluria market or expected to get launched during the study period. The analysis covers Primary Hyperoxaluria market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Primary Hyperoxaluria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Primary Hyperoxaluria Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market
Primary Hyperoxaluria Therapeutics Analysis
Companies across the globe are diligently working toward the development of novel treatment therapies for Primary Hyperoxaluria with a considerable amount of success over the years. Currently, several key players are diligently involved in developing new therapies. The emerging therapies are expected to launch in the coming years and are anticipated to transform the treatment dynamics.
Some of the key companies in the Primary Hyperoxaluria Market include:
-
Oxthera
-
Dicerna Pharmaceuticals
-
Allena Pharmaceuticals
-
Biocodex
And many others.
Primary Hyperoxaluria Therapies covered in the report include:
-
Oxabact
-
ALLN-177
-
Stiripentol
-
Nedosiran (DCR-PHXC)
And many more.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Primary Hyperoxaluria Competitive Intelligence Analysis
4. Primary Hyperoxaluria Market Overview at a Glance
5. Primary Hyperoxaluria Disease Background and Overview
6. Primary Hyperoxaluria Patient Journey
7. Primary Hyperoxaluria Epidemiology and Patient Population (In US, EU5, and Japan)
8. Primary Hyperoxaluria Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Hyperoxaluria Unmet Needs
10. Key Endpoints of Primary Hyperoxaluria Treatment
11. Primary Hyperoxaluria Marketed Products
12. Primary Hyperoxaluria Emerging Drugs and Latest Therapeutic Advances
13. Primary Hyperoxaluria Seven Major Market Analysis
14. Attribute Analysis
15. Primary Hyperoxaluria Market Outlook (In US, EU5, and Japan)
16. Primary Hyperoxaluria Access and Reimbursement Overview
17. KOL Views on the Primary Hyperoxaluria Market
18. Primary Hyperoxaluria Market Drivers
19. Primary Hyperoxaluria Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Bowel Management Systems Market
“Bowel Management Systems Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Bowel Management Systems. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Bowel Management Systems market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
, Oxthera, Dicerna, Allena Pharmaceuticals, Biocodex){kind=link}